CD8A and neoplasm: Oxaloate in combination with the PD-1 inhibitor pembrolizumab enhances CD8+ T-cell infiltration and inhibits tumor proliferation in a humanized mouse NSCLC model, thereby increasing sensitivity to immunotherapy [192].